25th March 2022 | Pharma Updates

Tata Trusts' IHF invests in a firm that developed a low-cost test to detect drug-resistant tuberculosis

HealSeq will be incubated at IISc and company specialises in biomarker development, precision medicine, and immunological profiling.

GMCH study finds that 58% of MDR-TB patients in the region are young people

As per study conducted by the pulmonary medicine department at GMCH, 58% of the 1,909 patients with multi-drug resistant tuberculosis were young people (19-39 years).

Imfinzi by AstraZeneca fails to improve survival in cervical cancer patients

Imfinzi, a cancer medication developed by AstraZeneca, failed to meet the primary endpoint in Phase III CALLA trial for patients with locally advanced cervical cancer.

COVID-19 has stalled TB research, so it must make up for lost time

According to the World Health Organization, 10 million people are expected to become ill with the disease by 2020, with 1.5 million of those cases resulting in death.

As per Moderna,the infant Covid vaccine trial was a success

Moderna announced that it is seeking regulatory approval for its Covid vaccine in children aged six months to six years after two-shot regimen was proved to be safe.

SMOFlipid Lipid injectable emulsion for pediatric patients approved by FDA

Fresenius Kabi announced that SMOFlipid Lipid Injectable Emulsion (ILE) has been given an additional indication for paediatric patients in the United States.

FDA denied approval of Sintilimab for NSCLC

FDA has issued a comprehensive response letter refusing approval of sintilimab injection in combination with pemetrexed and platinum chemotherapy as first-line treatment for NSCLC.

Fitbit's passive heart rate monitoring technology is being sought by Google for FDA approval

Google has submitted Fitbit’s passive heart rate tracking algorithm to the US Food and Drug Administration for assessment following a large-scale virtual health research.

HLT received FDA approval for two TAVR clinical studies

HLT stated that it has gained FDA permission for two clinical studies to evaluate the performance and safety of its HLT Meridian TAVR Valve System.

Cancer Drug Approvals from FDA might eventuate this Spring

Toripalimab plus chemotherapy in the first line, or toripalimab alone in the second and third lines, for recurrent or metastatic nasopharyngeal cancer.